APRIL HSU: Open Payments
NPI 1144989567 · HENDERSON, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,792 in 96 payments from 21 companies in 2025. Trend: 2023 $409 · 2024 $1,693 · 2025 $2,792
Food & beverage: $2,510Education: $194Consulting: $88
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 31 | $959 |
| GlaxoSmithKline, LLC. | 15 | $235 |
| AstraZeneca Pharmaceuticals LP | 6 | $230 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $204 |
| Galderma Laboratories, L.P. | 4 | $189 |
| GENZYME CORPORATION | 7 | $166 |
| Novartis Pharmaceuticals Corporation | 4 | $133 |
| ABBVIE INC. | 1 | $125 |
| Janssen Biotech, Inc. | 1 | $101 |
| SANOFI-AVENTIS U.S. LLC | 1 | $99 |
Products named: DUPIXENT, AIRSUPRA, NUCALA, NEMLUVIO, SKYRIZI, CUVITRU, TREMFYA, TAKHZYRO.
Industry payments across NV — which companies pay providers there.
